FTO and nonpapillary renal cell carcinoma: Genetic and pharmacologic inhibition of FTO reduced glutamine uptake, reductive carboxylation, and the GSH/GSSG ratio, leading to DNA damage and subsequently inhibiting ccRCC growth and survival.